Cybin Inc.从美国专利组织获得非致幻剂治疗物质专利的成分。 Cybin Inc. receives composition of matter patent for non-hallucinogenic treatments from USPTO.

Cybin Inc.是一家加拿大神经精神病公司,它从美国专利组织获得美国第一个物质专利,用于其临床前CYB005苯乙胺方案。 Cybin Inc., a Canadian neuropsychiatry firm, has received its first U.S. composition of matter patent from the USPTO for its preclinical CYB005 phenethylamines program. 该专利涵盖主要候选者,旨在对中枢神经系统紊乱进行非致幻性治疗。 This patent covers lead candidates aimed at non-hallucinogenic treatments for central nervous system disorders. 首席执行官Doug Drysdale强调,这一里程碑加强了他们的创新研究,同时正在实施的临床方案CYB003和CYB004,计划于2024年夏季对CYB003进行第三阶段试验。 CEO Doug Drysdale emphasized this milestone enhances their innovative research, alongside ongoing clinical programs CYB003 and CYB004, with a Phase 3 trial for CYB003 planned for summer 2024.